darglitazone previously known as cp is a member of the thiazolidinedione class of drugs and an agonist of peroxisome proliferator activated receptor ppar an orphan member of the nuclear receptor superfamily of transcription factors
it has a variety of insulin sensitizing effects such as improving glycemic and lipidemic control and was researched by pfizer as a treatment of metabolic disorders such as type diabetes mellitus
its development was terminated on november

